Cardiovascular comorbidity in rheumatic diseases

Nature Reviews Rheumatology

Volumn 11, Issue 12, 2015, Pages 693-704

  Nurmohamed, Michael T ^a   Heslinga, Maaike ^b   Kitas, George D ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Amsterdam Rheumatology and Immunology Center and Reade   (Netherlands)

^c RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 2; APOLIPOPROTEIN A1; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; ROFECOXIB; TOCILIZUMAB; TROPONIN I; VALDECOXIB;

ATHEROSCLEROSIS; BODY WEIGHT; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC ARTHRITIS; COMORBIDITY; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; ECHOGRAPHY; EVIDENCE BASED PRACTICE; HEART FAILURE; HEART INFARCTION; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MORTALITY; MYOCARDITIS; PERICARDITIS; PHYSICAL INACTIVITY; POPULATION RISK; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SMOKING HABIT; SPONDYLOARTHROPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID DISEASE; VALVULAR HEART DISEASE; CARDIOVASCULAR DISEASES; COMPLICATION; INFLAMMATION; PROGNOSIS; RHEUMATIC DISEASES;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; PROGNOSIS; RHEUMATIC DISEASES; RISK FACTORS;

EID: 84948720757     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2015.112     Document Type: Review

References (157)

1. Avina-Zubieta, J. A., Thomas, J., Sadatsafavi, M., Lehman, A. J.,&Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-Analysis of observational studies. Ann. Rheum. Dis. 71, 1524-1529 (2012
2. Nurmohamed, M. T., van der Horst Bruinsma, I.,&Maksymowych, W. P. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr. Rheumatol. Rep. 14, 415-421 (2012
3. Gabriel, S. E., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum. 48, 54-58 (2003
4. van Halm, V. P., et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann. Rheum. Dis. 68, 1395-1400 (2009
5. Lindhardsen, J., et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann. Rheum. Dis. 70, 929-934 (2011
6. Myasoedova, E.,&Gabriel, S. E. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr. Opin. Rheumatol. 22, 342-347 (2010
7. Solomon, D. H., et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107, 1303-1307 (2003
8. Turesson, C., Jarenros, A.,&Jacobsson, L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann. Rheum. Dis. 63, 952-955 (2004
9. Levy, L., Fautrel, B., Barnetche, T.,&Schaeverbeke, T. Incidence and risk of fatal myocardial infarction and stroke events in rheumatoid arthritis patients A systematic review of the literature. Clin. Exp. Rheumatol. 26, 673-679 (2008
10. Nicola, P. J., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 52, 412-420 (2005
11. Markusse, I M., et Al. Mortality in A Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated to Target for 10 Years [Abstract 817]. Arthritis Rheumatol. 66, S359 (2014
12. Widdifield, J., et al. Trends in excess mortality among patients with rheumatoid arthritis in Ontario, Canada. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.22553
13. Kitas, G., Banks, M. J.,&Bacon, P. A. Cardiac involvement in rheumatoid disease. Clin. Med. 1, 18-21 (2001
14. Mavrogeni, S., et al. Myocardial inflammation in autoimmune diseases: investigation by cardiovascular magnetic resonance and endomyocardial biopsy. Inflamm. Allergy Drug Targets 8, 390-397 (2009
15. Aydemir, M., et al. Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus. Lupus 19, 255-261 (2010
16. Adlan, A. M., Lip, G. Y., Paton, J. F., Kitas, G. D.,&Fisher, J. P. Autonomic function and rheumatoid arthritis-A systematic review. Semin. Arthritis Rheum. 44, 283-304 (2014
17. Peters, M. J., van der Horst-Bruinsma, I. E., Dijkmans, B. A.,&Nurmohamed, M. T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin. Arthritis Rheum. 34, 585-592 (2004
18. Papagoras, C., Voulgari, P. V.,&Drosos, A. A. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin. Exp. Rheumatol. 31, 612-620 (2013
19. Mathieu, S., Pereira, B.,&Soubrier, M. Cardiovascular events in ankylosing spondylitis: an updated meta-Analysis. Semin. Arthritis Rheum. 44, 551-555 (2015
20. Horreau, C., et al. Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J. Eur. Acad. Dermatol. Venereol. 27 (Suppl. 3), 12-29 (2013
21. Palazzi, C., Salvarani, C., DAngelo, S.,&Olivieri, I. Aortitis and periaortitis in ankylosing spondylitis. Joint Bone Spine 78, 451-455 (2011
22. Urowitz, M. B., et al. The bimodal mortality pattern of systemic lupus erythematosus. Am. J. Med. 60, 221-225 (1976
23. Manzi, S., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145, 408-415 (1997
24. Frostegård, J. Systemic lupus erythematosus and cardiovascular disease. Lupus 17, 364-367 (2008
25. Gustafsson, J. T.,&Svenungsson, E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity 47, 67-76 (2014
26. Narshi, C. B., Giles, I. P.,&Rahman, A. The endothelium: an interface between autoimmunity and atherosclerosis in systemic lupus erythematosus?. Lupus 20, 5-13 (2011
27. Li, J., et al. Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. Arthritis Rheum. 63, 492-502 (2011
28. Bichile, T.,&Petri, M. Prevention and management of co-morbidities in SLE. Presse Med. 43, e187-e195 (2014
29. Gonzalez, A., et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann. Rheum. Dis. 67, 64-69 (2008
30. Semb, A. G., et al. Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study. Ann. Rheum. Dis. 69, 1996-2001 (2010
31. Kavanaugh, A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann. Rheum. Dis. 53, 551-552 (1994
32. Robertson, J., Peters, M. J., McInnes, I. B.,&Sattar, N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat. Rev. Rheumatol. 9, 513-523 (2013
33. Choy, E.,&Sattar, N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 68, 460-469 (2009
34. Vermont, C. L., et al. Serum lipids and disease severity in children with severe meningococcal sepsis. Crit. Care Med. 33, 1610-1615 (2005
35. Myasoedova, E., et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482-487 (2011
36. Innala, L., et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res. Ther. 13, R131 (2011
37. Toms, T. E., et al. Are lipid ratios less susceptible to change with systemic inflammation than individual lipid components in patients with rheumatoid arthritis?. Angiology 62, 167-175 (2011
38. Toms, T. E., et al. Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 1025-1032 (2011
39. Charles-Schoeman, C., et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 67, 616-625 (2015
40. Toms, T. E., et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-Associated cardiovascular risk?. Ann. Rheum. Dis. 69, 683-688 (2010
41. Rollefstad, S., et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic. Ann. Rheum. Dis. 72, 1968-1974 (2013
42. Solomon, A., Norton, G. R., Woodiwiss, A. J.,&Dessein, P. H. Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study. Arthritis Res. Ther. 14, R67 (2012
43. Kremers, H. M., Nicola, P. J., Crowson, C. S., Ballman, K. V.,&Gabriel, S. E. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum. 50, 3450-3457 (2004
44. Summers, G. D., Metsios, G. S., Stavropoulos-Kalinoglou, A.,&Kitas, G. D. Rheumatoid cachexia and cardiovascular disease. Nat. Rev. Rheumatol. 6, 445-451 (2010
45. Metsios, G. S., et al. Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur. J. Cardiovasc. Prev. Rehabil. 16, 188-194 (2009
46. Stavropoulos-Kalinoglou, A., et al. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 72, 1819-1825 (2013
47. Metsios, G. S., et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann. Rheum. Dis. 73, 748-751 (2014
48. Wadley, A. J., et al. Three months of moderate-intensity exercise reduced plasma 3 nitrotyrosine in rheumatoid arthritis patients. Eur. J. Appl. Physiol. 114, 1483-1492 (2014
49. Chung, C. P., et al. Inflammation-Associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 58, 2105-2112 (2008
50. Giles, J. T., et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol. 67, 626-636 (2015
51. Dessein, P. H., Joffe, B. I.,&Stanwix, A. E. Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. J. Rheumatol. 30, 1403-1405 (2003
52. van den Oever, I. A., van Sijl, A. M.,&Nurmohamed, M. T. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther. Adv. Musculoskelet. Dis. 5, 166-181 (2013
53. Stavropoulos-Kalinoglou, A., et al. Anti-Tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012
54. Solomon, D. H., et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 305, 2525-2531 (2011
55. Stolt, P., et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann. Rheum. Dis. 62, 835-841 (2003
56. Wolfe, F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J. Rheumatol. 27, 630-637 (2000
57. Klareskog, L., Malmstrom, V., Lundberg, K., Padyukov, L.,&Alfredsson, L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin. Immunol. 23, 92-98 (2011
58. Hyrich, K. L., Watson, K. D., Silman, A. J.,&Symmons, D. P. Predictors of response to anti TNF α therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45, 1558-1565 (2006
59. Abhishek, A., Butt, S., Gadsby, K., Zhang, W.,&Deighton, C. M. Anti TNF α agents are less effective for the treatment of rheumatoid arthritis in current smokers. J. Clin. Rheumatol. 16, 15-18 (2010
60. Stavropoulos-Kalinoglou, A., et al. Cigarette smoking associates with body weight and muscle mass of patients with rheumatoid arthritis: a cross-sectional, observational study. Arthritis Res. Ther. 10, R59 (2008
61. Panoulas, V. F., et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47, 1286-1298 (2008
62. Boyer, J. F., Gourraud, P. A., Cantagrel, A., Davignon, J. L.,&Constantin, A. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-Analysis. Joint Bone Spine 78, 179-183 (2011
63. Protogerou, A. D., et al. Arterial hypertension assessed out of office in a contemporary cohort of rheumatoid arthritis patients free of cardiovascular disease is characterized by high prevalence, low awareness, poor control and increased vascular damage-Associated white coat phenomenon. Arthritis Res. Ther. 15, R142 (2013
64. Dougados, M., et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann. Rheum. Dis. 73, 62-68 (2014
65. Panoulas, V. F., et al. Galectin 2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis. Clin. Exp. Hypertens. 31, 93-104 (2009
66. Panoulas, V. F., et al. Polymorphisms of the endothelin 1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium 15, 203-212 (2008
67. Panoulas, V. F., et al. Transforming growth factor-β1 869T/C, but not interleukin 6 174G/C, polymorphism associates with hypertension in rheumatoid arthritis. Rheumatology (Oxford) 48, 113-118 (2009
68. Wong, M., et al. Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum. 48, 81-89 (2003
69. Klarenbeek, N. B., et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Ann. Rheum. Dis. 69, 1342-1345 (2010
70. Sandoo, A., et al. Anti-TNFα therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J. Hum. Hypertens. 25, 699-702 (2011
71. Panoulas, V. F., et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 46, 1477-1482 (2007
72. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-Analysis. JAMA 288, 2015-2022 (2002
73. Morgan, S. L., Baggott, J. E., Lee, J. Y.,&Alarcón, G. S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J. Rheumatol. 25, 441-446 (1998
74. van Ede, A. E., et al. Homocysteine and folate status in methotrexate-Treated patients with rheumatoid arthritis. Rheumatology (Oxford) 41, 658-665 (2002
75. Martí-Carvajal, A. J., Solà, I.,&Lathyris, D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD006612. http://dx.doi.org/10.1002/14651858.CD006612.pub4
76. Palomino-Morales, R., et al. A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res. Ther. 12, R71 (2010
77. Ichiki, T. Thyroid hormone and atherosclerosis. Vascul. Pharmacol. 52, 151-156 (2010
78. Raterman, H. G., et al. Increased progression of carotid intima media thickness in thyroid peroxidase antibodies-positive rheumatoid arthritis patients. Eur. J. Endocrinol. 169, 751-757 (2013
79. Gonzalez-Gay, M. A., et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum. 57, 125-132 (2007
80. Gonzalez-Juanatey, C., et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am. J. Med. 114, 647-652 (2003
81. Rodríguez-Rodríguez, L., et al. TNFA 308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 216, 125-130 (2011
82. Rodriguez-Rodriguez, L., et al. CCR5?32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study. Arthritis Res. Ther. 13, R133 (2011
83. López-Mejías, R., et al. NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 224, 426-429 (2012
84. Toms, T. E., et al. Apolipoprotein E gene polymorphisms are strong predictors of inflammation and dyslipidemia in rheumatoid arthritis. J. Rheumatol. 39, 218-225 (2012
85. Toms, T. E., Symmons, D. P.,&Kitas, G. D. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr. Vasc. Pharmacol. 8, 301-326 (2010
86. Dimitroulas, T., et al. Relationship between dimethylarginine dimethylaminohydrolase gene variants and asymmetric dimethylarginine in patients with rheumatoid arthritis. Atherosclerosis 237, 38-44 (2014
87. Kaptoge, S., et al. C reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-Analysis. Lancet 375, 132-140 (2010
88. Liang, K. P., et al. Autoantibodies and the risk of cardiovascular events. J. Rheumatol. 36, 2462-2469 (2009
89. Kremers, H. M., Crowson, C. S., Therneau, T. M., Roger, V. L.,&Gabriel, S. E. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 58, 2268-2274 (2008
90. Maradit-Kremers, H., et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 76-80 (2007
91. Rho, Y. H., et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 61, 1580-1585 (2009
92. Dessein, P. H., et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J. Rheumatol. 32, 435-442 (2005
93. Sattar, N., McCarey, D. W., Capell, H.,&McInnes, I. B. Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 108, 2957-2963 (2003
94. Libby, P., Ridker, P. M.,&Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135-1143 (2002
95. Lerman, A.,&Zeiher, A. M. Endothelial function: cardiac events. Circulation 111, 363-368 (2005
96. Anderson, T. J., et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol. 26, 1235-1241 (1995
97. Sandoo, A., Veldhuijzen van Zanten, J. J., Metsios, G. S., Carroll, D.,&Kitas, G. D. Vascular function and morphology in rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 50, 2125-2139 (2011
98. Karpouzas, G. A., et al. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann. Rheum. Dis. 73, 1797-1804 (2014
99. Semb, A. G., et al. Carotid plaque characteristics and disease activity in rheumatoid arthritis. J. Rheumatol. 40, 359-368 (2013
100. Douglas, K. M., et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann. Rheum. Dis. 65, 348-353 (2006
101. Aubry, M. C., et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J. Rheumatol. 34, 937-942 (2007
102. Zöller, B., Li, X., Sundquist, J.,&Sundquist, K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am. J. Cardiovasc. Dis. 2, 171-183 (2012
103. Gasparyan, A. Y., Ayvazyan, L., Mikhailidis, D. P.,&Kitas, G. D. Mean platelet volume: a link between thrombosis and inflammation?. Curr. Pharm. Des. 17, 47-58 (2011
104. Gasparyan, A. Y., Stavropoulos-Kalinoglou, A., Mikhailidis, D. P., Douglas, K. M.,&Kitas, G. D. Platelet function in rheumatoid arthritis: arthritic and cardiovascular implications. Rheumatol. Int. 31, 153-164 (2011
105. Chung, W. S., et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann. Rheum. Dis. 73, 1774-1780 (2014
106. Bengtsson, A., Zöller, B., de Frutos, P. G., Dahlbäck, B.,&Sturfelt, G. Factor V:Q506 mutation and anticardiolipin antibodies in systemic lupus erythematosus. Lupus 5, 598-601 (1996
107. Pahor, A., et al. Antiphospholipid antibodies as a possible risk factor for atherosclerosis in patients with rheumatoid arthritis. Immunobiology 211, 689-694 (2006
108. Mavrogeni, S., Dimitroulas, T., Sfikakis, P. P.,&Kitas, G. D. Heart involvement in rheumatoid arthritis: multimodality imaging and the emerging role of cardiac magnetic resonance. Semin. Arthritis Rheum. 43, 314-324 (2013
109. Mavrogeni, S., et al. Myocarditis as a precipitating factor for heart failure: evaluation and 1 year follow-up using cardiovascular magnetic resonance and endomyocardial biopsy. Eur. J. Heart Fail. 13, 830-837 (2011
110. Mavrogeni, S., Dimitroulas, T.,&Kitas, G. D. Multimodality imaging and the emerging role of cardiac magnetic resonance in autoimmune myocarditis. Autoimmun. Rev. 12, 305-312 (2012
111. Yndestad, A., et al. Role of inflammation in the progression of heart failure. Curr. Cardiol. Rep. 9, 236-241 (2007
112. Gonzalez-Juanatey, C., et al. Echocardiographic and Doppler findings in long-Term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin. Arthritis Rheum. 33, 231-238 (2004
113. Davis, J. M. 3rd et al. The presentation and outcome of heart failure in patients with rheumatoid arthritis differs from that in the general population. Arthritis Rheum. 58, 2603-2611 (2008
114. Bell, C.,&Rowe, I. F. The recognition and assessment of cardiovascular risk in people with rheumatoid arthritis in primary care: a questionnaire-based study of general practitioners. Musculoskeletal Care 9, 69-74 (2011
115. Ikdahl, E., et al. EULAR task force recommendations on annual cardiovascular risk assessment for patients with rheumatoid arthritis: an audit of the success of implementation in a rheumatology outpatient clinic. Biomed. Res. Int. 2015, 515280 (2015)
116. DAgostino, R. B. Sr et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743-753 (2008
117. Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M.,&Cook, N. R. C reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118, 2243-2251 (2008
118. Ridker, P. M., Buring, J. E., Rifai, N.,&Cook, N. R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297, 611-619 (2007
119. Hippisley-Cox, J., et al Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336, 1475-1482 (2008
120. Conroy, R. M., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24, 987-1003 (2003
121. Peters, M. J., et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325-331 (2010
122. Perk, J., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Int. J. Behav. Med. 19, 403-488 (2012
123. Arts, E. E., et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann. Rheum. Dis. 74, 668-674 (2015
124. Arts, E. E., et al. Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-206879
125. Stone, N. J., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1-S45 (2014
126. Kawai, V. K., et al. The ability of the 2013 American College of Cardiology/American Heart Association cardiovascular risk score to identify rheumatoid arthritis patients with high coronary artery calcification scores. Arthritis Rheumatol. 67, 381-385 (2015
127. Tournadre, A., et al. Application of the European Society of Cardiology, Adult Treatment Panel III and American College of Cardiology/American Heart Association guidelines for cardiovascular risk management in a French cohort of rheumatoid arthritis. Int. J. Cardiol. 183, 149-154 (2015
128. Maradit-Kremers, H., et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402-411 (2005
129. Gonzalez-Juanatey, C., et al. Increased prevalence of severe subclinical atherosclerotic findings in long-Term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 82, 407-413 (2003
130. Gonzalez-Juanatey, C., Llorca, J., Martin, J.,&Gonzalez-Gay, M. A. Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin. Arthritis Rheum. 38, 366-371 (2009
131. Corrales, A., et al. Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann. Rheum. Dis. 73, 722-727 (2014
132. Eder, L., Chandran, V.,&Gladman, D. D. The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. Ann. Rheum. Dis. 73, 1990-1996 (2014
133. López-Mejías, R., et al. Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. J. Rheumatol. 42, 39-45 (2015
134. Dessein, P. H., et al. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J. Rheumatol. 41, 429-436 (2014
135. López-Mejías, R., et al. Angiopoietin 2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 31, 761-766 (2013
136. Dimitroulas, T., et al. B type natriuretic peptide in rheumatic diseases: a cardiac biomarker or a sophisticated acute phase reactant?. Autoimmun. Rev. 11, 837-843 (2012
137. Panoulas, V. F., et al. Serum uric acid is independently associated with hypertension in patients with rheumatoid arthritis. J. Hum. Hypertens. 22, 177-182 (2008
138. Daoussis, D., et al. Uric acid is a strong independent predictor of renal dysfunction in patients with rheumatoid arthritis. Arthritis Res. Ther. 11, R116 (2009
139. Panoulas, V. F., et al. Association of serum uric acid with cardiovascular disease in rheumatoid arthritis. Rheumatology (Oxford) 46, 1466-1470 (2007
140. Daoussis, D.,&Kitas, G. D. Uric acid and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 50, 1354-1355 (2011
141. Daoussis, D., et al. Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation. Clin. Rheumatol. 30, 477-484 (2011
142. Gasparyan, A. Y., Stavropoulos-Kalinoglou, A., Toms, T. E., Douglas, K. M.,&Kitas, G. D. Association of mean platelet volume with hypertension in rheumatoid arthritis. Inflamm. Allergy Drug Targets 9, 45-50 (2010
143. Sandoo, A., et al. Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. Rheumatology (Oxford) 54, 1145-1152 (2015
144. Dimitroulas, T., Sandoo, A.,&Kitas, G. D. Asymmetric dimethylarginine as a surrogate marker of endothelial dysfunction and cardiovascular risk in patients with systemic rheumatic diseases. Int. J. Mol. Sci. 13, 12315-12335 (2012
145. Wloch, A., Wieczorek-Surdacka, E., Sulicka-Grodzicka, J., Kruszelnicka, O.,&Surdacki, A. Asymmetric dimethylarginine reflects cumulative inflammatory burden in rheumatoid arthritis. Rheumatology (Oxford) 54, 1135-1136 (2015
146. Blankenberg, S., et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121, 2388-2397 (2010
147. Ford, E. S., et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N. Engl. J. Med. 356, 2388-2398 (2007
148. McCarey, D. W., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363, 2015-2021 (2004
149. Moodley, I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc. J. Afr. 19, 102-107 (2008
150. Solomon, D. H., et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 59, 1097-1104 (2008
151. Roubille, C., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-Analysis. Ann. Rheum. Dis. 74, 480-489 (2015
152. del Rincón, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M.,&Escalante, A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol. 66, 264-272 (2014
153. Ridker, P. M. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J. Thromb. Haemost. 7 (Suppl. 1), 332-339 (2009
154. Greenberg, J. D., et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 576-582 (2011
155. van Sijl, A. M., et al. The effect of TNF-α blocking therapy on lipid levels in rheumatoid arthritis: a meta-Analysis. Semin. Arthritis Rheumatol. 41, 393-400 (2011
156. Souto, A., et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-Analysis. Arthritis Rheumatol. 67, 117-127 (2015
157. Glund, S.,&Krook, A. Role of interleukin 6 signalling in glucose and lipid metabolism. Acta Physiol. (Oxf.) 192, 37-48 (2008